A Phase III readout in September 2024 for rocatinlimab, on which Amgen and Kyowa Kirin were collaborating in atopic dermatitis, appeared underwhelming to analysts, with Jefferies noting that the data ...
A 2015 law required the state Department of Toxic Substances Control to overhaul its permitting process to consider how ...